FORM PTO-1449/A and B (modified PTO/SB/08)

APPLICATION NO.: 10/627,413 FILING DATE: July 25,2003

1648

ATTY, DOCKET NO. C1639 70079US00 CONFIRMATION NO.: 3204

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

11

APPLICANT: Krieg et al.

GROUP ART UNIT:

EXAMINER: Emily M. Le

HE PATENT DON'HOUSEN'TE

	U.S. Patent Do	Custieni	Neme of Patenius or Applicant of Cited	Date of Publication or have
nitials (1996).	Number	Kind Code	Document	of Ched Document MM-DD-YYYY
	5,457,189		Crocks et al.	10-10-1995
	5,567,604		Rando et al.	10-22-1996
	5,665,580		Crooke et al.	09-09-1997
	5,681,944		Crooke et al.	10-28-1997
	5,858,987		Bear-Ramero et al.	Ø1-12-1999
	6,221,882	131	Macfarlane	04-24-260)
	6,399,630	Bi	Macfarlane	06-04-2002
	6,479,564	81	Macfarlene of al.	11-12-2002
	6,521,637	82	Macfarlane	02-18-2003
	6,589,940	81	Raz et al.	07-08-2003
	6,727,236	81	Huscherson et al.	04-27-2004
	6,821,957	81	Krieg et al.	11-23-2094
	6,943,240	82	Bauer et al	09-13-2005
	6,949,520	81	Hartmann et al.	09-27-2005
	7,901,890	131	Wagner et al.	02-21-2006
	7,223,741	B2	Krieg	05-29-2007
	7,271,156	82	Krieg et al.	07-18-2007
	2001-0044416	IA [	McCluskie et al.	11-22-2961
	2002-0086839	Al	Roz et al.	07-04-2002
	2002-0091097	Al	Bratzler et al.	07-11-2002
	2002-0164341	Al	Davis et al	11-07-2002
	2902-0165178	Al	Schetter et al	11-07-2002
	2002-0198165	Al	Eraizior et al.	12-26-2002
	2003-0026782	Al	Krieg	02-02-2063
	2003-0026801	Al	Worner et al.	62-66-2003
	2003-0050768	A)	Kricg to al.	03-13-2003
	2003-0055014	À	Bratzler	03-29-2003
	2003-0091599	Al	Davis et al.	05-15-2003
	2003-0100527	Al	Krieg et al.	05-29-2093
	2003-0139364	Al	Krieg et al.	07-24-2063
	2003-0148316	Al	Lipford et al.	08-07-2063
	2013-0148976	1.41	Kries et al.	08-67-2663

	<i></i>
ENAMINER.	DATE CONSIDERED:
Æ.L./	(32/18/2008

<sup>\*</sup> EXAMBER. Institi if extresses considered, whether or acceleration is in conformance with MPEP 609. On white through challon it was in conformance and ner considered ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

2004-0171571

2004-0181045

2004-0198680

2004-0198688

2004-6229835

A:

A:

A:

Al

Al

09-02-2004

09-16-2004

10-07-2804

11-18-2004

FS-Wel	o Rece	ipt date	12/17/2	007		1	0627413 - GAU: 16	
FORM PTO-1449/A and B (modified PTO/SB/08)  APPLICATION NO.: 10/627,413							ATTY: DOCKET NO.: C1019.76079US60	
INFORMATION DISCLOSURE		FILING	FILING DATE: July 25,2603 CONFIR		FION NO.: 3204			
	JEMENT BY APPLICANT			APPLI	CANT: Krieg et al.			
Sheet		T 6f T	łi	GROU	P ART UNIT: 1648	EXAMINER.	Emily M. Le	
	T	2003-0166	i001	AI	Lipford		09-94-2003	
***************************************		2003-0181	466	A)	Schefter et al.		09-25-2003	
***************************************		2903-0191	679	Al	Krieg et al.		19-09-2003	
		2003-0224	010	Al	Davis ci al.		12-04-2603	
	T	2003-0232	074	A!	Lipford et al.		12-18-2003	
		2003-0232	:856	A)	Mecfariane	***************************************	12-18-2003	
		2003-0232	780	Al	Carsos el al.		12-18-2003	
		2004-0006	Q10	Al	Carson et al.		01-08-2004	
***************************************		2004-0006	i034	Al	Raz et af.	***************************************	01-08-2004	
***************************************		2004-0009	949	AI	Krieg		01-15-2004	
***************************************		2004-0030	1118	A)	Wagner et al.		02-12-2004	
		2004-0053	880	AI	Krieg		03-18-2004	
***************************************	1	2004-0067	962	A9	Braizier et al.		04-08-2004	
	1	2004-0067	905	Al	Krieg		04-08-7004	
		2004-0087	7534	Al	Krieg et al.	***************************************	05-06-2094	
		2004-0081	1538	TA1	Krieg et al.	***************************************	05-06-2064	
***************************************		2004-0092	472	Al	Krieg	***************************************	65-13-2604	
***************************************	11	2004-0106	S68	TAI	Krieg et al.		06-03-2004	
	1	2004-0113	219	AI	Ahn et al.	***************************************	06-17-2004	
	1	2004-0131	628	TAI	Bratzler et al.	***************************************	07-08-2064	
***************************************	1	2004-0132	***************************************	AI	Kricg et al.		07-08-2004	
***************************************	1	2004-0142	469	14	Krieg et al.	***************************************	07-22-2604	
	1	2004-0143	1132	AI	Krieg et al.	***************************************	07-22-2004	
	1	2004-0147	*******	TA1	Krieg et al.		07-29-2004	
	1	2064-0152	649	A)	Krieg	***************************************	08-05-2004	
***************************************	1	2004-0152		Al	Krieg et al.		08-05-2004	
	1	2004-0152	657	NI.	Krieg et al.	***************************************	08-03-2004	
		2004-0162	258	AL	Krieg et al.		08-19-2004	
	1	2004-0162	*********	AI	Krieg et al.	***************************************	08-19-2004	
		2004-0167	/089	Al	Krieg et a).		08-26-2004	
***************************************	1	2004-0171	156	A)	Krieg et a).		69-02-2084	
		2004 0179		·•	Marina ment	~~~~~	26 22 4624	

EXAMINER:	DATE CONSIDERED:
ÆL/	02/18/2008

Krieg et al.

Krieg et al.

Krieg et al.

Krieg et at.

Krieg

FEXAMINES. Initial if reference considered, whether or nectionion is in conformance with MPEP 65%. There have through similar as in conformance and not contridered include copy of this form with east composition to Applicate.

ALL REFERENCE CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./ 1298574.1

2005-0100983

2005-0101554

2005-0101557

2005-0119273

2005-0123523

2005-0130911

2005-0148532

2005-0169888

2005-0171047

2005-0181422

2005-0182017

2005-0197314

Al

Αŧ

Al

Al

Al

AI

AL

ΑI

Al

A)

Al

A:

05-12-2005

05-12-2005

05-12-2005

06-02-2005

06-09-2005

06-16-2005

07-07-2005

08-04-2005

98-04-2005

08-18-2005

08-18-2005

L. 121 - A A Car	Jinecelpi date. 12/1//2	1002/413 - GAU: 16			
SORIA DTO	1449/A and B (modified FTE)/SB/08)	APPLI	CATION NO.: 10/627,413	ATTY, DOCKET NO.: C1009,70079US0	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		PILIN	3 DATE: July 25,2003	CONFIRMATION NO : 3204	
		APPLI	CANT: Krieg et al.		
Shaar	3 1 of 31	- GROU	PARTUNIT. 1648	EXAMINER: Emily M. Le	
	2904-0234512	Al	Wagner et al.	111-25-2004	
	2004-6235770	A3	Davis et al.	11-25-2004	
	2904-0235774	Al	Braizler et al.	11-25-2004	
	2004-0235777	Al	Wagner et al.	11-25-2004	
***************************************	2004-0235778	A)	Wagner et al.	11-25-2004	
	2004-0266719	Ai	McCluskie et al.	12-30-2004	
	2905-0004061	Al	Krieg er si.	81-06-2005	
	2005-0004062	A)	Krieg et al.	01-06-2005	
	2005-0009774	A)	Kneg er al.	01-13-2005	
	2005-0031638	A1	Dalemans et al.	92-10-2005	
	2005-0032734	Al	Davis et al.	02-10-2605	
	2005-6032736	A1	Krieg et al.	02-10-2005	
***************************************	2005-0037403	Al	Krieg et al.	02-17-2005	
	2005-0037985	AI	Krieg et al.	02-17-2065	
	2005-0043529	AL	Davis et al.	02-24-2005	
	2005-0049215	Al	Krieg et al.	03-03-2005	
	2005-6049216	[A]	Krieg et al.	03-03-2005	
	2005-0054601	Ai	Wagner et al.	03-10-2005	
	2005-0054602	AI	Krieg et al.	03-10-2005	
	2005-6059619	Al	Krieg et al.	03-17-2005	
***********	2005-0059625	Al	Krieg et al.	03-17-2005	
	2005-9670491	A!	Krieg et al.	03-31-2005	
	2005-8075362	AI	Hutcherson et al.	04-07-2005	
	2004-0092468	Al	Schwartz et al.	05-13-2004	

2005-0197314	A! Krieg	et al.	09-08-2005	
EXAMINER		DATE CONSIDERED:		
/E L /			92/18/2008	
<b></b>		1		

Bauer et al.

Krieg et al.

Krieg et al.

Lipford et al

Krieg et al.

Krieg et al.

Krieg et al.

Bauer et al.

Krieg

Ublmans et al.

Hartman et al.

<sup>\*</sup> EXAMINEER, Initial if externor considered, whether or execusion is in conformance with MPEF 669. Draw time amongh clustion if not in conformance and not considered Include capy of Visi form with east communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./ 1198974.1

FORM PTOLE	449/A and B (modified PTG/9B/08)	APPLI	CATION NO.: 10/627,413	ATTY DOCKE	T NO.: C1039.70079US90	
		FILIN	FILING DATE. July 25, 2003 CONFIRMATION NO.: 3204			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: Krieg et al				
Sheet			PARTUNIT: 1648	EXAMINES:	Emily M. Le	
	7005-0715501	I A I	Lipford et al.			
	2005-0213095	~f~~~~~~			9-29-2605	
	2005-0233999	<u>  A1</u>	Krieg et al.		0-20-2005	
	2805-0239732	<u> </u>	Kneg et al.	·····	0-20-2005	
	u	<u> </u>	Krieg et al.	·····	0-27-2005	
	2065-0239733	IAI	Jurk et al.	***************************************	0-27-2005	
	2005-0239734	AÎ	Ubimann et al.	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	0-27-2005	
	2605-0239736	Al.	Krieg et a).	······································	0-27-2005	
	2605-0244379	A)	Krieg et al		1-63-2065	
	2005-0244380	Al	Krieg et al.	~~~~ <del>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</del>	1-03-2005	
	2005-0245477	Al	Krieg et al.	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	1-03-2605	
	2005-0250726	Al	Krieg et a).		1-10-2005	
	2005-0256073	A)	Lipford et al.		1-17-2005	
	2005-0267064	Al	Krieg et al.	and processing the second	2-01-2005	
	2005-6277604	Al	Krieg et al.	************************	2-15-2005	
	2005-0277609	AI	Krieg et a).		2-15-2005	
	2006-0003955	A1	Krieg et al		1-05-2096	
	2006-0063962	Al	Abhovalia et al.		1-05-2006	
	2006-0019916	IAI	Krieg et al.		1-24-2006	
	2006-0019923	AI	Davis et al.	0	1-26-2006	
	2606-0658251	A)	Krieg et al.	0	3-16-2006	
	2006-0089326	A)	Krieg et al.	8	4-27-2006	
	2006-0094683	Al	Krieg et al.	10	5-04-2006	
	2006-0149875	Al	Krieg et al.	10	6-29-2006	
	2006-0154890	Αî	Bratzier st al.	0	7-13-2006	
	2006-0172966	A)	Lipford et al.	0	8-03-2006	
	2006-0188913	A)	Krieg et al.	0	8-24-2005	
	2006-0211639	Al	Bratzier et al.	0	9-21-2004	
	2006-0211644	A1	Krieg et al.	(	9-21-2006	
	2006-0729271	AI	Krieg et a).	[ ]	0-12-2006	
	2006-0241076	Aï	Uhlmann et al.	[ ]	0-26-2006	
	2006-0246035	Al	Ahloweliz et al.	[]	1-02-2006	
	2006-0286070	Al	Hartmann et al.	1	2-21-2006	
	2006-0287263 -	Al	Davis et al.	1	2-21-2006	
	2007-0009482	Al	Krieg et al.	0	1-11-2007	
1	2007-0010470	Al	Krieg et al.	0	1-11-2007	
***************************************		·				

			2007-0037767	A)	Bratzle	et al.	02-15-2007
						,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
50	AMINER-					DATE CONSIDERED:	
-		15	A. /			02/18/200	\$

A)

<sup>\*</sup> EXAMITER: Initial if reference considered, whether or notclassium is in conformance with MPEP 609, Draw time through change change in moreformance and not considered. lackets sops of the disease with mast commitmentation to Applicate.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./ 1298674.1

an orrest tracempt eater. (2.13)) ac	V i			0027410 " CIMO. 1040
FORM PTG-1449/A and B (modified PTO/S9/08)	APPLICATION NO.:	10/627,413	ATTY, OXXX	KET NO.: C1039.70079US60
INFORMATION DISCLOSURE	FILING DATE:	July 25,2093	CONFIRMAT	(ION NO., 3204
STATEMENT BY APPLICANT	APPLICANT.	Krieg et at.		***************************************
Sheet 5 of 11	GROUP ART UNIT:	1648	EXAMINER	Emily M. Le
A	***************************************	***************************************	***************************************	
2007-0065467	Al Krieg et al			93-22-2907

2007-0065467	Αl	Krieg et al.	03-22-2907
2007-0086553	A3	Kneg et al	63-22-2607
2007-0066554	Αl	Krieg et al.	03-22-2007
2607-0078164	ΑI	Krieg et a).	04-05-2007
2007-0129320	A9	Davis et al.	06-07-2007
2007-0142315	ΑI	Forsback et al.	06-21-2007
2007-0184465	Αl	Wagner et al.	08-09-2007
2007-0202128	A3	Krieg et al	08-30-2007
2007-0224210	Al	Krieg of al.	09-27-2007
2607-0232622	AI	Lipford et al.	10-04-2607

FOREIGN PATENT DOCUMENTS

Examinar's	Cite	Foreign Patent Dreument			Name of Patentee or Applicant of Cired	Sate of	·····
initials *	No	Office/ Country	Namber	Kind Code	Document	Publication of Cited Documents MM-DD-YYYY	Translation (Y/H)
		wo	99/56755	AL	University of Iowa Research Foundation	11-11-1999	
	*	wo	00/06588	Al	University of love Research Foundation	02-19-2000	
		wo.	90/14217	A2	CPG Immunopharmaceuticals GMBH	03-16-2000	
	*	wo	90/67023	Al	CPG Immunopharmaceuticals GMBH	11-09-2000	***************************************
	*	WO	2004/007743	A2	Coley Phirmaceutical GMBH	01-22-2004	
	*	wo	2004/026888	A2	Coley Pharmaceutical GMBH	04-01-2904	
		wo	2004/094671	A2	Coley Pharmacentical GMBH	11-04-2004	
		WO	2006/080946	A2	Cofey Pharmaceutical GMBH	08-03-2006	
	*	WO	2007/031877	A2	Coley Pharmaceutical GM8H	03-22-2007	
L	<u> </u> *	wo	2007/038720	A2	Coley Pharmaceutical GMBH	04-05-2007	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite	lischude name of the author (in CAPITAL LETTERS), title of the arnels (when appropriate), title of the isen (book, magazine, jouenal, script, symposium, caralog, etc.), dare, page(s), volume-issus number(s), publisher.	Translation
tuicas.	No	city and/or country where published.	(Y/N)
	*	Press Release, January 2007, "Coley Pharmaceutical Group Updates Hapatitis C Drug Development	
		Strategy".	
	4	Press Release, hime 2007, "Coley Pharmacoutical Group Announces Pfizer's Discontinuation of	
		Chrical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small	
	L	Ceil Lung Cancer".	
	*	AGRAWAL or at , Medicinal cliemitity and therapeutic potential of CpG DNA. Trends Mol Med.	
		2092 Mar(#(3):114-21.	
	*	ANITESCU et al., Interleukis-10 fusictions in vitro and in vivo to inhibit bacterial DNA-induced	
1	<u> </u>	secretion of interletik in-12. J Interferon Cytokine Res. 1997 Dec;17(12):781-8.	

EXAMINER	DATE CONSIDERED:
#L/	02:18/2968

<sup>\*</sup> EXAMINER: finish if reference considered, whether or nativitation is in conformance with MPEP 609. Dawn line duringly difference and not considered include copy of the firm with east nonnewledge to Applicate.

ALL PEFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

m. 2.4400 (1000lar date) 12/11/2001			1902/9	10 , 7350. 104
PORM PTO-1449/A and is (inciding PTO/SB/08) INBORMATION DISCLOSURE	APPLICATION NO.:	19/627,413	ATTY, DOCKET NO.:	C1039.76079U900
	FILING DATE:	July 25,2003	CONFIRMATION NO.:	3204
STATEMENT BY APPLICANT	APPLICANT.	Krieg et al.	***************************************	
Sheet 6 of 11	GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le
			***************************************	***************************************

			***************************************
	*	BRANDA et al., B-cell proliferation and differentiation in common variable immunodeficiency	
		patients produced by an actismose oligomer to the revigenc of HIV-1. Clin Immunol Immunopathol	
		1996 May(79(2):115-21.	
	*	CHACE et al., Becterial DNA-induced NK cell IFN-gamme production is dependent on	***************************************
		macrophage secretion of IL-12. Clin Immuno) Immunopathol. 1997 Aug;84(2):185-93.	
***************************************	*	COSSUM et al., Disposition of the 14C-labeled phosphorothicate oligonucleuside ISIS 2105 after	***************************************
		intravenous administration to rats. J Pharmacol Exp Ther. 1993 (Dec; 267(3):118)-90.	
	*	COWSERT et al., In vitro evaluation of phosphorothicate oligonucleotides targeted to the E2	************************
	1	mRNA of papillomavirus: potential freatment for genetal warts. Antimicrob Agents Chemother	
		1993 Feb;\$7(2):171-7.	
***************************************		FIELDS et al., Fields' Virology, 2001;1:1153	
		HSIER et al., incorporation of CpG oligodeoxynucleoride fails to enhance the protective officacy of	***************************************
		a subunit veccine against Mycobacterium tuberculosis. Vaccine. 2004 Jan 26;22(5-6):655-9.	
***************************************		KATAOKA et al., Immunomerapeutic potential in guinea-pig tumor model of deoxyribonucleic	
	-	acid from Mycobacterium bovis BCG complexed with poly-L-lysine and carboxymethylcellulose.	
		Jon J Med Sci Biol. 1996 Oct;43(5):171-82.	
		KOVARIX et al., CpG oligodeoxynecieotides can circumvent the Th2 polarization of neonatal	***************************************
		responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J	
	1	Immunoi, 1999 Feb 1;162(3):1611-7.	
		KRUEG et al., Lymphocyte activation mediated by oligodeoxymiciotrides or DNA containing govel	
	1	un-methylated CpG motifs. American College of Rheumstology 58th National Scientific Merzing.	
	-		
		Minnespolis, Minnesons, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl).	
		KRIEG et al., Bacterial DNA or oligonucleotides contaming CpG motifs project mice from lethal L.	
	1	monocytogenes challenge. 1996 Meeting on Molecular Approaches to the Control of Infectious	
		Diseases. Cold Spring Hurbor Laboratory, Saptember 9-13, 1996-116.	***************************************
	1 *	KRIEG et al., Unmethylated CpG DNA protects mice from lethal listeria monocytogenes challenge.	
		Vaccines 1997; 97:77-9.	*************
		KRIEG et al., Infection, In: McGrew Hill Book, 1996;242-3	
	1 *	KRIEG et al., Lymphocyte activation by CpG disselected motifs in prokaryotic DNA. Teends	
		Mismbiol. 1996 Feb:4(2):73-6.	
		KRIEG at at., Induction of systemic TH1-like instate immunity in normal volunteers fullowing	
		subcutaneous but not intravenous administration of CPO 7909, a synthetic B-class CpG	
		aligodeaxynacleatide TLR9 agonist. J.Immanather. 2004 Nov-Der;27(6):469-71.	
		KRIEG, Therapeutic potential of Toll-like receptor 9 activation, Nat Rev Drug Discay, 2006	
		Jun;3(6),471-84	
	*	KULKARNI et al., Effect of dietary racleotides on response to becterial infections.	
	1	JPEN J Parenter Enteral Nutr. 1986 Mar-Apr;10(2):169-71.	
	*	EURAMOTO at al., Induction of T-cell-mediated immusity against MethA fibrosarooms by	***********
	*	intratumural injections of a bacrilus Calmette-Guerin nucleic acid fraction. Cancer Immunol	
		Immanather, 1992;34(5):283-8	
************	*	KURAMOTO et al., Changes of host cell infilmation into Meth A fibrosarcome tumor during the	
		course of regression induced by injections of a BCG nucleic acid fraction. Int J Immenopharmacol.	
		1992 Jul; 14(5):773-82.	
************	***************************************		**********

,	
EXAMINEK:	DATE LONDIDERED:
	The state of the s

FORM PTO-1449/A and B (modified PTO/SB/IR) INFORMATION DISCLOSURE

APPLICATION NO.: 10/627,413 ATTY, DOCKET NO.: C1039.76679US00 SILING DATE: July 25,2003 CONFIRMATION NO.: 3204

STATEMENT BY APPLICANT 3 of. Sheet

APPLICANT: Krieg et al. GROUP ART UNIT: 1648 EXAMINER: Emily M. Le

] *	KURAMOTO et al., in satu infiltration of natural killer-like calls induced by intradernal injection of	***************************************
	the nucleic sold fraction from BCG. Microbiol Immunol, 1989;33(11):929-40.	
	LIU et at., Recombinant interfeukin-6 protects mice against experimental hacterial infection. Infect Inmun. 1992 Oct.69(10):4402-6.	
*	PISETSKY et al., immunulogical properties of bacterial DNA. Ann N Y Acad Sci. (595 Nov 27:772:152-63.	***************************************
•	RANKIN et al., CpG metif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Numleic Acid Drug Dev. 200). Oct;11(5):333-40.	***************************************
	F.AZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. ACR Poster Session C: Cytokines and inflammatory Mediators, 1996 Det 26: Abstract 615.	
*	SATOH et al., The study of mechanisms in CpG oligodeoxynucleotides-induced aggravation in murine altergic contact dermittiis to 2,4-dimitrofluorobenzene. Fükushima Igaku Zazehi. 2002;57(3):247-50.	***************************************
*	SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. I Interferon Cytokine Ret. 1996 Oct;16(10):799-803.	***************************************
*	STEIN et al., Problems is interpretation of data derived from in vitro and in vivo use of antisense of objections of objectives objectives of objectives objectives of objectives objectives of objectives objective objective objective objectives objective objecti	*****
*	STEIN et al., Non-unisense effects of oligodeoxynucleotides. Antisense Technology (997; ch)1: 241-64.	
*	STEIN et al., Anisense oligonucleotides as therapeutic agents—is the bullet really magical? Science. 1993 Aug 20,261(5124):1004-12.	
×	THREADGILL et at., Mitogenic synthetic polynucleotides suppress the antibudy response to a bacterial polysaccharide. Vaccine. 1998 Jan 16(1):76-82.	
•	WAAG et al., injection of inactivated phase I Coxiella burnetri increases non-specific testatance to infection and stimulates lymphukine production in mice. Ann N Y Acad Sci. 1990;590;203-14.	*****
*	Y AMAMOTO et al., [Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of nligonucleonide fraction extracted from Mycobacterium bovis BCQ] Kekkaku. 1994 Sep.69(9):571-4. Inspinese.	Y-Abs
*	ZEFAC) et al., Pattern and kinetics of cytokine production following administration of phosphorodioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997 (Oct;7(5):49):-502.	***************************************
*	Patent Interference No. 105,171, lowa Preliminary Motion 3 (for judgment based on failure to comply with 35 U.S.C. 135(b)). (Electronically filed, insigned), June 7, 2004.	
*	Patent interference No. 105,171. Iowa Preliminary Motion 4 (for judgment of no interference in facts (Electronically filed, unsigned). June 7, 2014.	
*	Patent Interference No. 105,171. Iowa Preliminary Motion 5 (for judgment based on lack of enablament) (Electronically filed, unsigned), hone 7, 2004	
*	Patent Interference No. 105,171, Iowa Preliminary Motion 6 (for judgment based on lack of adequate swritten description), (Electronically filed, unsigned). June 7, 2004.	
	Patent interference No. 105,171. lowa Preliminary Motion 7 (motion to redefine interference to designate claims as not corresponding to the Count) (Electronically filed, unsigned), June 7, 2004.	

EXAMINED.	DATE CONSIDERED:

<sup>\*</sup> BX/AMPRIP\* Institut if reference considered, whether or nateriation is in conformance with MPEP 609, Draw Sere through custom if and in scandomance will not confidence include copy of this form with expt organization to Applicate.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO: 1449/A and B (modified PTO/SB/BB)  INFORMATION DISCLOSURE		APPLICATION NO	10/627,413	ATTY, DOCKET N	O.: C1039.7	6079US00		
		FILING DATE: July 25,2003 CONFIRMATION NO.: 3204				***************************************		
		CRY APPLI		APPLICANT:	Krieg es al.		***************************************	•••••••••••••••••••••••••••••••••••••••
Shoot	8	of I	11	GROUP ART UNIT:	1648	EXAMINER:	Emily A	1. Le
	å		**************					***************************************
***************************************	7.7	1 Daraus Insasta		198 371 Jama Brettenia	an Marian & facas	ingent motion to redefi		
				fied, unsigned). June 7		miken monen m izazi	ac usc	
						ion for benefit of earlies		
				ally filed, unsigned). Ju		1331 713 ALMEN IN CAL PORT 15/2		
						tingent motion to reder	fra the	***************************************
		unterference b	y adding a	continuation application	n) (Electronically	filed, unsigned), July 2	, 2004.	
	*					fornia Opposition 3 (to	Towa	***************************************
				r judgment under 35 U				
	*					fomia Opposition 4 (to	fows	***************************************
				r judgment of no interfe				
	*	Patent Interfe	rence No.	105,171. Regents of the	University of Cali	fornia Opposition 5 (to	lowa	
				r judgment that UC's c				***************************************
	*	Patent interfe	rense No.	195,171. Regents of the	University of Cali	fornia Opposition 6 (to	Iowa	
		2004.	totton ti to	r judgment based on la-	ck ot adednate wut	ten description). Septer	nber 9,	
······			narna No	100 17) Dazama of dea	The bounder of Cafe	forala Opposition 7 (to	·	***************************************
				redefine the interferent			10WB	
						fomia Opposition 8 (to	Dates	
				redefine the Cause). Se		commence of the		
						fornia Response 9 (to I		
		Contingent M	otion 9 for	benefit). September 9,	2004.			
***************************************	*					fornia Opposition 10 (t	o lowa	***************************************
				redefine the interferen				
	*					fornia Opposition 11 (t	o lows	
				suppress). October 15.		***************************************		*******************
	*					Preliminary Motion 3	for [	
				C. §135(b)) (Electronic		<ol> <li>October 15, 2004.</li> <li>Proliminary Motion fo</li> </ol>		
	1	of a interfer	mae in fea	i) (Electronically filed,	(se sopport or rows	i Proiminary Motion to	t Inakweur	
	*	Potent Interfer	ranca hin	18C 191 Laug Benfu C	Gamman of these	Preliminary Motion 5		
						, unsigned). October 15		
						Preliminary Motion 6		******************************
						ically filed, unsigned).		
		15, 2004.						
	*	Parent Interfe	rence No	105,171 kowa Reply 7	(in support of lowe	Preliminary Motion 7	to redefine	~~~~~~~~~~
		the interferen	ca) (Elecin	onically filed, unsigned	). October 15, 2084	ŧ		
	1.					Preliminary Motion 8	to redefine	***************************************
				y filed, unsigned). Octo				
	*	Patent interfe	rence No.	195,171. lowa Reply 10	(in support of low	a Preliminary Motion	i 0 to	*******************************

ENAMINER:	DATE CONSIDERED.

redefine the interference) (Electronically filed, unsigned). October 15, 2004.

Patent Interference No. 105,171, Iowa Neply 11 (in support of lowa Miscellaneous Motion to

suppress). (Electronically filed, unsigned). October 18, 2004

<sup>\*</sup>EXAMPLE. Initial of afference consistent, whether or notatation in in conformance with MPEP 609, Drow hire disregit extains of not in conformance and not considered.

Internals repy of 96s four with each commissions on a Applicate

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ELL/

Description.

FORM PTO-1449/A and B (modified PTO/SW68)  INFORMATION DISCLOSURE	APPLICATION NO.:	10/627,413	ATTY, DOCKET NO.:	C1039.76079U500	
	FILING DATE	July 25,2003	CONFIRMATION NO.	3264	
STATEMENT BY APPLICANT		APPLICANT:	Krieg et al.		***************************************
	Shee: 9 Of 31	GROUP ART UNIT-	1648	EXAMINER:	Emily M. Le
***		•••••		***************************************	

	*	Patent Interference No. 195,171, Regents of the University of California Preliminary Statemens.  June 7, 2004.	
***************************************			
		Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 1 (to designate additional claims of lows patent as corresponding to the Count). June 7, 2004.	
***********	***************************************	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 2 (for	
		judgment based on lack of written description support and introducing new matter). June 7, 2004	
***************************************		Pricent Interference No. 165,171. Regents of the University of California Preliminary Motion 3 (for	
		judgment based on anticipation). June 7, 2904	
		Paient Interference No. 105,171. Regense of the University of California Prefiminary Motion 4 (for	
		judgment based on obviousness), June 7, 2004.	
		Petent Interference No. 105,171. Regents of the University of California Preliminary Motical 5 (for	
	1	judgment based on anticipation). June 7, 2004	
	1 7	Patent Interference No. 105,171. Regenus of the University of California Preliminary Motion 6 (for	
		judgment based on inequitable conduct). June 7, 2014.	
	1 *	Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary	
		Motion 7 (for banefit of an earlier application under 37 CFR 1.633(j)). July 2, 2604.	
		Parent interference No. 105,171. Regents of the University of California Contingent Preliminary	
		Motion 8 (to add additional claims under 37 CFR 1.633(c)(2) and (i)), July 2, 2004.	
		Amended Claims for Application Number 09/265,191, filed March 10, 1999.	
	*	Patent Interference No. 105,171, Iowa Opposition 1 (opposition to motion to designate additional	
		claims as corresponding to the Count) (Electronically filed, unsigned). September 9, 2004.	
	*	Patent Interference No. 105,171, lows Opposition 2 (opposition to motion for judgment based on	
		lack of written description support and infroducing new matter) (Electronically filed, unsigned).	
		September 9, 2004	
	***************************************	Patent Interference No. 195,171. Iowa Opposition 3 (opposition to motion for judgment based on	***************************************
		anticipation) (Electronically fifed, unsigned), September 9, 2004.	
	***************************************	Patent Interference No. 105,171, Iowa Opposition 4 (opposition to motion for judgment based on	***************************************
		obvinumess) (Electronically filed, unsigned), September 9, 2004.	
		Patent Interference No. 195,171, lows Opposition 5 (apposition to mation for judgment based on	***************************************
		anticipation) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 195,171, Iowa Opposition 6 (opposition to motion for judgment based on	
		inequilable conduct) (Electronically filed, unsigned). September 9, 2004	
***************************************		Patent Interference No. 105,171. Iowa Opposition 7 (opposition to motion for benefit of an earlier	
		application under 7 CFR 1.633(j)) (Electronically filed, unsigned), September 9, 2004	
		Parent Interference No. 105,171, fowa Opposition 8 (opposition to motion to add additional claims	***************************************
		under 37 CFR 1.633 (2) and (i)) (Einstronically filed, unsigned). Sessember 9, 2004.	
		Fatent Interference No. 105,171. Reacons of the University of California Reply 1 (to lowe's	
	1	opposition to UC's motion to designate lowe claims as corresponding to the Count). October 15,	
		opposition to Ot. 5 motion to designate lower claims as corresponding to the County October 15, 2004.	
***************************************		Parent Interference No. 105,171 Regents of the University of California Reply 2 (to Jowa's	***************************************
		opposition to UC Preliminary Motion 2 for Judgment). October 15, 2604,	
		Patent Interference No. 105,171 Regents of the University of California Reply 3 (to Jowa's	
		Opposition to UC Preliminary Motion 3 for Judgmens). October 15, 2004.	
		1 Spanner v Coveren preserv v respons State 1, 20%	

EXAMINEP.	DATE CONSIDERED.	
		-

<sup>\*</sup>EXAMPLE: Italia I it effections considered, whether or not include in its uniformatises with MPEP 609, Draw line through climics of and an conformation and not considered to base copy of that form with nonexconstantial control (Application of Application Company) and the conformation of the conformation

EFS-Web Hedelpt date: 12/17/20	106274	13 - GAU: 164		
FORM PTO-1449/A and 8 (modified PTO/SB/08)	APPLICATION NO.:	10/627,413	ATTY, DOCKET NO:	C1039,70679US60
INFORMATION DISCLOSURE	FILING DATE:	July 25,2003	CONFIRMATION NO.	3204
STATEMENT BY APPLICANT	APPLICANT:	Krieg er al	***************************************	
Shoot 10 UF (1	GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le

	1*	Patent Interference No. 105,171. Regents of the University of California Reply 4 (to lowe's	***************************************
		Opposition to UC Pretiminary Motion 4 for Judgment), October 15, 2604.	
	*	Patent Interference No. 105,171. Regents of the University of California Reply 5 (to lowe's	***************************************
		Opposition to UC Prehminary Motion 5 for Judgment). October 15, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Reply 6 (to Jowa's	
		opposition to UC Preliminary Motion 6 for judgment). October 15, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Reply 7 (to lowa's	
		Opposition to UC Preliminary Motion 7 for Benefit), October 15, 2004.	
***************************************	*	Potent Interference No. 105,171. Regents of the University of California Reply 8 (to Jowa's	***************************************
	ì	Opposition to UC Preliminary Motion 8 to add additional claims). October 15, 2064.	
***************************************	*	Patent Interference No. 105,171. Decision on Motion under 37 CFR §41.125. March 10, 2005.	
***************************************	§	Patent interference No. 105,171. Judgment and Order, March 10, 2005.	
***************************************	***************************************	Pateni interference No. 105,171. Regents of the University of California, Brief of Appellant, July 5,	
	į	2005.	
***************************************	<del></del>	Patent Interference No. 105,171. University of lows and Coasy Pharmaceutical Group, Inc. Brief of	
		Appetiges, Appast 17, 2005.	
		Patent Interference No. 103,171. Regents of the University of California. Reply Brief of Appellant.	
		September 6, 2003.	
		Patent Interference No. 103,171. Regents of the University of California, Decision of CAFC, July	
		17, 2056.	
		Patent Interference No. 103,526. Krieg Substantive Menon 1 (for unpatentability based on	
	-	interference estopped; (Electronically filed, nosigned);	
		Patent Interference No. 105,526 Krieg Substantive Motion 2 (for judgment based on inadequate	***************************************
		written description and/or enablement). (Electronically filed, unsigned). June 18, 2007.	
		Patent Interference No. 103,326. Kring Contingent Responsive Motion (to add new claums 164 and	
	1	105). (Electronically filed, insigned). July 25, 2007.	
		Patent Interference No. 105,526. Krieg Substantive Motion 3 (for judgment based on prior art).	
	1	(Bischmarkally filed, unsigned). June 18, 2607	
	1	Patent Interference No. 105,526, Raz Motion 1 (Unpatentability of Krieg Clums under 35 U.S.C. §	
		112, First Paragraph) (Electronically filed, unsigned), June 18, 2007.	
		Patent Interference No. 105,526, Raz Motion 2 (Raising a Threshold Issue of No Interference-in-	
***************************************		Facs) (Electronically filed, onsigned), June 18, 2007.	
		Patent Interference No. 105,526. Baz Motion J (Krieg's Claims are Unpatentable Over Prior An	
		Under 35 U.S.C. § 192(b)) (Electromically filed, unsigned), June 18, 2007.	
	*	Patent Interference No. 105,526. Haz Motion 4 (To Designate Krieg Claims 46 and 82-84 as	
		Corresponding to Count 1). (Electronically filed, unsigned). June 18, 2067.	
	-	Patent Interference No. 1815,526. Raz Responsive Miscellaneous Motion 5 (To revive the Baz	
		Parent Application) (Electronically filed, unsigned) July 25, 2007.	
	*	Parent Interference No. 105,526. Raz Contingent Responsive Motion 6 (To Add a New Claim 58)	
		(Electronically files, nasigned) July 25, 2007.	
	*	Patent Interference No. 105,526 Krieg Opposition   (Opposition to Median for Lack of Englishment)	
		and Written Description) (Electronically filed, unsigned) Sentember 16, 2007.	
			3

EXAMINER	DATE COMSIDERED:
Æ1.1	92/18/2008

<sup>\*</sup> EXAMINES Initial if reference considered, whether or productation is in conformance with MPEP 609, Draw line through citations if not in conformance and incident copy of this from with acceptance produce of conformance.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

		Patent Interference No. 105,526. Krieg Opposition 2 (to Raz Motion 2) (Electronically filed,	
		unsigned) September 19, 2007.	
	***************************************	Patent Interference No. 105,526. Krieg Opposition 3 (To Paz Morion 3) (Electronically filed,	**********
		unsiged) September 10, 2007.	
***********	*	Patent Interference No. 195,526. Krieg Opposition 4 (Opposition to Motion for Designating Claima	
		46 and 82-84 as Corresponding to the Court) (Electronically filed, unsigned) September 10, 2007.	
	*	Pagent Interference No. 185,526. Krieg Opposition 6 (Opposition to Raz Contingent Responsive	
		Motion 6) (Electronically filed, unsigned) September 10, 2007.	
	*	Patent Interference No. 103,526. Raz Opposition 1 (Opposing Krieg Substantive Motion 1)	
		(Electronically filed, ensigned) September 10, 2907.	******
		Palent Interference No. 105,526, Raz Opposition 2 (Opposing Kring Substantive Motion 2)	
		(Electronically filed, unsigned) September 10, 2007.	*****
		Patent Interference No. 105,526. Raz Opposition 4 (Opposing Krieg Contingent Responsive Motion	
		to Add New Claims 194 and 105) (Electronically filed, unsigned) September 10, 2007.	
.,,		Prient Interference No. 105,526. Krieg Reply 1 (Beply to Raz opposition 1) October 5, 2607	
		Paters Interference No. 105,526 Kneg Reply 2 (Reply to Raz opposition 2) October 5, 2007	•••••
		Patent Interference No. 105,526, Krieg Reply 4 (Reply to Ritz opposition 4) October 5, 2007	*******
	*	Parent Interference No. 105,526. Raz Reply 1 (Reply to Krieg opposition 1) October 5, 2007	
	*	Patern Interference No. 105,526. Rex Reply 2 (Reply to Krieg opposition 2) October 5, 2007	
	*	Patent Interference No. 103,526. Raz Reply 3 (Reply to Krieg opposition 3) October 5, 2007	
	8	Patent Interference No. 105,326, Raz Reply 4 (Reply to Krieg opposition 4) October 5, 2007	
	*	Patent Interference No. 105,526. Raz Reply 6 (Reply to Krieg opposition 6) October S, 2007	
		Patent Interference No. 103,526. Krieg Miscellaneous Motion 5 (To exclude exhibits 2066, 2070,	
		2071, 2672, 2673, 2074, 2075, 2076 and 2078) October 9, 2007.	***********
		Patent Interference No. 105,526. Raz Opposition 5 (Opposing Krieg Miscellaneous Motion 5)	
		October 25, 2007.	
		Parent Interference No. 105,526. Raz Miscellaneous Motion 7 (To exclude evidence) October 19,	
		2867.	
	*	Palent Interference No. 105,526. Krieg Opposition 7 (To Raz Miscellaneous Motion 7) October 25,	
		Paient Interference No. 105,526. Krieg Reply 3 (Reply to Kaz opposition 5) October 36, 2007	**********
	*	Patent Interference No. 105,526 Raz Reply 7 (Reply to Krieg opposition 7) October 30, 2007.	

<sup>\*</sup>a copy of this reference is not provided as it was provided as it was provided by the control of the office of a prior application, Serial No. 09/630,319, filed hely 31, 2000 and/or 15/147.429. Blod July 2, 2002, and relied upon the an surface Blog date under 15 U.S.C. 120 (commentum, community or part, and divinantal applications).

PACTE — No comics of U.S. patents, published U.S. patent applications, or pending, ungalished patent applications stored at the USPTO's Image File Wrapper (PW) system, are included. See 17 CFR §6.98 and 128 POC163. Copics of all other patently), publication(s), unpublished, pending U.S. patent applications, or other information has due provided as required by 37 CFR \$1.08 union () each copies were provided in an IDE in an earlier application that complets with 37 CFR \$1.08 union () for earlier application is related upon for an earlier filing due under 35 U.S.C. §120.]

EXAMINEE:	DATE CONSIDERED
Æmily Ls/	62/18/2008

<sup>\*</sup> EXAMBLE Initial if reference considered, whether is not resident in in owtermance with MPEP 600; Draw line through citation if sea in conformance and not considered include copy of this form with next come ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. Æ LJ